Roger B. Cohen
University of Pennsylvania
193 Papers
1.2K Citations
Roger B. Cohen is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 37, co-authored 193 publications. Previous affiliations of Roger B. Cohen include Fox Chase Cancer Center.
Chat about Author
Papers
Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.
Melina E. Marmarelis,Jeffrey C. Thompson,Charu Aggarwal,Tracey L. Evans,Erica L. Carpenter,Roger B. Cohen,Corey J. Langer,Joshua Bauml +7 more
TL;DR: The use of circulating tumor DNA (ctDNA), so-called "liquid biopsies", has emerged as a promising technique to molecularly profile tumors non-invasively and is becoming increasingly utilized in the routine management of lung cancer.
500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028
Patrick A. Ott,Sarina Anne Piha-Paul,Pamela N. Munster,Michael J. Pishvaian,E. van Brummelen,Roger B. Cohen,Carlos Gomez-Roca,Samuel Ejadi,Mark N. Stein,Emily Chan,Matteo Simonelli,Anne Morosky,S.S. Yuan,Minori Koshiji,Jaafar Bennouna +14 more
17
Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase
Suzanne F. Jones,Roger B. Cohen,E. C. Dees,Y. Lee,J. A. Papas,M. R. Cooper,Katherine M. Galvin,H. A. Burris +7 more
TL;DR: MLN8054 was in general rapidly absorbed, displayed dose-proportionate exposure to benzodiazepines, and inhibition of Aurora A kinase in basal epithelial cells was assessed.
17
Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results
Charu Aggarwal,Roger B. Cohen,Matthew P. Morrow,Joshua Bauml,Gregory S. Weinstein,Jean D. Boyer,Xuefei Shen,Jian Yan,Jessica Goldenberg,Drishty Nashit,Sandra Oyola,Jessica Lee,Laurent Humeau,David B. Weiner,Zane Yang,Mark L. Bagarazzi,David B. Weiner +16 more
TL;DR: DNA-based Immunotherapy with plasmids encoding HPV16 and HPV18 E6/E7 antigens has been shown to generate robust immune responses in women with HPV-driven high-grade cervical dysplasia.
16
Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGF{beta} receptor involved in tumor angiogenesis.
Laura W. Goff,F. de Braud,Roger B. Cohen,Jordan Berlin,Cristina Noberasco,Hossein Borghaei,Erjian Wang,D. Hu Lowe,Wendy J. Levin,Corrado Gallo-Stampino +9 more
TL;DR: PF-03446962 is a first in class mAb anti ALK-1, safe and with manageable toxicities, mainly characterized by asymptomatic elevation of pancreatic enzymes and transient platelet decreases.
16